IDIOPATHIC PULMONARY FIBROSIS (IPF)
Clinical trials for IDIOPATHIC PULMONARY FIBROSIS (IPF) explained in plain language.
Never miss a new study
Get alerted when new IDIOPATHIC PULMONARY FIBROSIS (IPF) trials appear
Sign up with your email to follow new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to slow lung scarring in IPF patients
Disease control Not yet recruitingThis study tests whether adding dextromethorphan to nidanib helps people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. About 60 adults aged 40 and older with mild to moderate lung damage will receive either the combination or a…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Disease control
Last updated May 17, 2026 05:46 UTC
-
Stem cells aim to slow lung scarring in early trial
Disease control Not yet recruitingThis early-phase study tests a stem cell product called REGEND007 in 12 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing difficulty. Participants receive the stem cells through an IV and are monitored for 12 weeks to check safety …
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: EARLY_PHASE1 • Sponsor: Regend Therapeutics • Aim: Disease control
Last updated May 17, 2026 05:36 UTC
-
Experimental therapy targets scar cells in fatal lung disease
Disease control Not yet recruitingThis early-stage trial tests a new cell therapy for people with end-stage idiopathic pulmonary fibrosis (IPF), a severe lung scarring disease. The therapy uses specially engineered immune cells to target and calm the cells that cause scarring. The study will check if the treatmen…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: PHASE1 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated May 17, 2026 05:35 UTC
-
New drug BC006 aims to slow lung scarring in fibrosis patients
Disease control Not yet recruitingThis study tests a new drug, BC006, in 96 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and makes breathing hard. The trial has two parts: first, a small group gets BC006 to check safety; then, patients are randomly assigned to receive eithe…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: PHASE2 • Sponsor: Dragonboat Biopharmaceutical Company Limited • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
Could inhaled stem cell particles help repair scarred lungs?
Disease control Not yet recruitingThis early study tests whether inhaling tiny particles from stem cells (called extracellular vesicles) is safe for people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs. Nine adults will receive different doses twice daily for a week, with monitoring for…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: PHASE1 • Sponsor: Huan Ye • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New lung drug faces off against standard treatment in major trial
Disease control Not yet recruitingThis study tests a new drug, deupirfenidone, against the current standard treatment pirfenidone for people with idiopathic pulmonary fibrosis (IPF), a lung disease that gets worse over time. About 1,100 adults will take one of the two drugs three times a day for up to three years…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: PHASE3 • Sponsor: PureTech • Aim: Disease control
Last updated May 01, 2026 16:01 UTC
-
Massive study aims to unravel mysteries of lung scarring disease
Knowledge-focused Not yet recruitingThis study will observe nearly 3,000 people with idiopathic pulmonary fibrosis (IPF), a serious lung disease that causes scarring. Researchers want to learn how the disease changes over time and how it affects patients' symptoms, lung function, and quality of life. The goal is to…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Sponsor: Henan University of Traditional Chinese Medicine • Aim: Knowledge-focused
Last updated May 17, 2026 05:51 UTC
-
1,000-Patient trial to test ancient herbal remedies against deadly lung disease
Knowledge-focused Not yet recruitingThis study will follow 1,000 people with idiopathic pulmonary fibrosis (IPF) to see if traditional Chinese medicine can help manage the disease. Researchers will track how often patients have sudden worsening of symptoms and how long they live without the disease getting worse. T…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Sponsor: Henan University of Traditional Chinese Medicine • Aim: Knowledge-focused
Last updated May 17, 2026 05:34 UTC
-
Talking therapy may help lung disease patients manage symptoms at home
Knowledge-focused Not yet recruitingThis study tests whether motivational interviewing—a type of counseling—delivered through video calls can help people with idiopathic pulmonary fibrosis (IPF) improve their self-care. About 124 adults with IPF will take part. The goal is to see if this approach helps them better …
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS (IPF)
Phase: NA • Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated May 15, 2026 11:55 UTC